Global Cardiac Biomarkers Testing Market
Marktgröße in Milliarden USD
CAGR :
% 
 Prognosezeitraum |
2023 –2030 |
 Marktgröße (Basisjahr) | USD 12,098.97 Billion |
 Marktgröße (Prognosejahr) | USD 28,491.13 Billion |
 CAGR |
% |
| Wichtige Marktteilnehmer |
Global Cardiac Biomarkers Testing Market, By Type (Myocardial muscle Creatine Kinase (CK-MB), Troponins (T and I), Myoglobin, Brain Natriuretic Peptide (BNPs) or NT-proBNP, Ischemia Modified Albumin (IMA)), Application (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis), Location of Testing (Point of Care, Laboratory) – Industry Trends and Forecast to 2030.
Cardiac Biomarkers Testing Market Analysis and Size
According to the World Health Organization, approximately 4.77 million people in India suffer from cardiovascular diseases, with obesity causing angina pectoris in approximately 3.1% of the population. To reduce the burden of disease, the Government of India is launching a number of initiatives to raise awareness in rural areas. Several government and private healthcare institutes and diagnostic laboratories are implementing cardiac biomarkers diagnostic test kits to meet the growing patient population.
Data Bridge Market Research analyses that the cardiac biomarkers testing market which is USD 12098.97 million in 2022, is expected to reach USD 28491.13 million by 2030, at a CAGR of 11.30% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Cardiac Biomarkers Testing Market Scope and Segmentation
|
Report Metric |
Details |
|
Forecast Period |
2023 to 2030 |
|
Base Year |
2022 |
|
Historic Years |
2021 (Customizable to 2015 - 2020) |
|
Quantitative Units |
Revenue in USD Million, Volumes in Units, Pricing in USD |
|
Segments Covered |
Type (Myocardial muscle Creatine Kinase (CK-MB), Troponins (T and I), Myoglobin, Brain Natriuretic Peptide (BNPs) or NT-proBNP, Ischemia Modified Albumin (IMA)), Application (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis), Location of Testing (Point of Care, Laboratory) |
|
Countries Covered |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
|
Market Players Covered |
F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (U.S.), Abbott (U.S.), QIAGEN (Germany), PerkinElmer, Inc. (U.S.), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (U.S.), Enzo Biochem, Inc. (U.S), Charles River Laboratories (U.S.), Eurofins Scientific (Luxembourg), Agilent Technologies, Inc. (U.S.), Bruker (U.S.), Siemens (Germany), Epigenomics AG (Germany), General Electric (U.S.) |
|
Market Opportunities |
|
Market Definition
Cardiac markers, also known as cardiac biomarkers, are released into the bloodstream when the heart is stressed or its muscles are damaged. These markers include enzymes, hormones, and proteins such as cardiac troponins, creatine kinase (CK), ischemia-modified albumin (IMA), and myoglobin. The measurement and testing of these markers can aid in the diagnosis of heart conditions such as cardiac ischemia and acute coronary syndrome (ACS). At the moment, the triage and diagnostic systems used to determine the risk of these conditions are based on electrocardiograms (ECGs) and clinical history.
Cardiac Biomarkers Testing Market Dynamics
Drivers
- Rising prevalence of cardiovascular diseases
With the rising prevalence of cardiovascular diseases, the demand for these diagnostic test kits is expected to rise in the coming years. According to WHO, the mortality rate from heart failure is rising, accounting for more than 15.60% of total deaths in the country. To slow the rate of increase, the government and healthcare organizations are taking preventive measures to educate the public about the benefits of these test kits. As a result of the above-mentioned factors, the market for cardiac biomarkers testing is expected to grow during the forecast period.
- Rising prevalence of coronary heart disease
The rising prevalence of coronary heart disease has increased the number of cases of angina pectoris/chest pain, particularly among the elderly. According to the World Health Organization, nearly 17 million people died from cardiovascular diseases in 2019. Around 20% of those were diagnosed with angina pectoris. In addition, as millennials consume unhealthier foods, the prevalence of angina pectoris has increased. As a result, demand for cardiac biomarkers testing is expected to rise in order to meet the growing patient population.
Opportunities
- Government Initiatives
In the outbreak of COVID-19, governments around the world have launched a number of initiatives to improve healthcare infrastructure. Increasing healthcare spending, particularly in emerging economies such as India, South Korea, and Japan, has increased demand for advanced medical devices such as cardiac biomarkers diagnostic test kits. According to the India Brand Equity Foundation (IBEF), the Government of India approved the continuation of the "National Health Mission" in the Union Budget for 2021-22 with a budget of US$ 5.10 billion. Under this policy, the government will provide advanced medical devices in rural areas for cardiology, neurology, and other diseases in order to reduce global mortality. A slew of such initiatives around the world are expected to create market growth opportunities.
Restraints/Challenges
- Side effects associated with cardiac biomarkers
Rising side effects such as skeletal muscle injury and limited specificity in some cases will obstruct market growth and will further challenge the growth of the cardiac biomarkers testing market during the forecast period.
This cardiac biomarkers testing market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the cardiac biomarkers testing market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In 2021, Roche announced the launch of five new intended uses for two key cardiac biomarkers using Elecsys technology high sensitive cardiac troponin T (cTnT-hs) and N-terminal pro-brain natriuretic peptide test (NT-proBNP). These biomarkers aid in managing cardiovascular disease and can assist clinicians in diagnosing heart attacks and managing heart failure.
- In 2021, Baxter International Inc., a global leader in acute care, will collaborate with bioMérieux, a global leader in in vitro diagnostics, to launch the CE marking of the NEPHROCLEARTM CCL14 Test.
Global Cardiac Biomarkers Testing Market Scope
The cardiac biomarkers testing market is segmented on the basis of type, application and location of testing. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Myocardial muscle Creatine Kinase (CK-MB)
- Troponins (T and I)
- Myoglobin, Brain Natriuretic Peptide (BNPs)
- NT-proBNP
- Ischemia Modified Albumin (IMA)
Application
- Myocardial Infarction
- Congestive Heart Failure
- Acute Coronary Syndrome
- Atherosclerosis
Location of Testing
- Point of Care
- Laboratory
Cardiac Biomarkers Testing Market Regional Analysis/Insights
The cardiac biomarkers testing market is analyzed and market size insights and trends are provided by country, type, application and location of testing as referenced above.
The countries covered in the cardiac biomarkers testing market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the cardiac biomarkers testing market because of increased demand for cardiac testing, high CVD prevalence, and increased awareness of cardiac diagnostics solutions.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 because of the region's rising modernization, rising disposable incomes, and rising affordability.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The cardiac biomarkers testing market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for cardiac biomarkers testing market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the cardiac biomarkers testing market. The data is available for historic period 2011-2021.
Competitive Landscape and Cardiac Biomarkers Testing Market Share Analysis
The cardiac biomarkers testing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to cardiac biomarkers testing market.
Some of the major players operating in the cardiac biomarkers testing market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Thermo Fisher Scientific Inc. (U.S.)
- Abbott (U.S.)
- QIAGEN (Germany)
- PerkinElmer, Inc. (U.S.)
- Merck KGaA (Germany)
- Bio-Rad Laboratories, Inc. (U.S.)
- Enzo Biochem, Inc. (U.S.)
- Charles River Laboratories (U.S.)
- Eurofins Scientific (Luxembourg)
- Agilent Technologies, Inc. (U.S.)
- Bruker (U.S.)
- Siemens (Germany)
- Epigenomics AG (Germany)
- General Electric (U.S.)
SKU-
Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud
- Interaktives Datenanalyse-Dashboard
- Unternehmensanalyse-Dashboard für Chancen mit hohem Wachstumspotenzial
- Zugriff für Research-Analysten für Anpassungen und Abfragen
- Konkurrenzanalyse mit interaktivem Dashboard
- Aktuelle Nachrichten, Updates und Trendanalyse
- Nutzen Sie die Leistungsfähigkeit der Benchmark-Analyse für eine umfassende Konkurrenzverfolgung
Forschungsmethodik
Die Datenerfassung und Basisjahresanalyse werden mithilfe von Datenerfassungsmodulen mit großen Stichprobengrößen durchgeführt. Die Phase umfasst das Erhalten von Marktinformationen oder verwandten Daten aus verschiedenen Quellen und Strategien. Sie umfasst die Prüfung und Planung aller aus der Vergangenheit im Voraus erfassten Daten. Sie umfasst auch die Prüfung von Informationsinkonsistenzen, die in verschiedenen Informationsquellen auftreten. Die Marktdaten werden mithilfe von marktstatistischen und kohärenten Modellen analysiert und geschätzt. Darüber hinaus sind Marktanteilsanalyse und Schlüsseltrendanalyse die wichtigsten Erfolgsfaktoren im Marktbericht. Um mehr zu erfahren, fordern Sie bitte einen Analystenanruf an oder geben Sie Ihre Anfrage ein.
Die wichtigste Forschungsmethodik, die vom DBMR-Forschungsteam verwendet wird, ist die Datentriangulation, die Data Mining, die Analyse der Auswirkungen von Datenvariablen auf den Markt und die primäre (Branchenexperten-)Validierung umfasst. Zu den Datenmodellen gehören ein Lieferantenpositionierungsraster, eine Marktzeitlinienanalyse, ein Marktüberblick und -leitfaden, ein Firmenpositionierungsraster, eine Patentanalyse, eine Preisanalyse, eine Firmenmarktanteilsanalyse, Messstandards, eine globale versus eine regionale und Lieferantenanteilsanalyse. Um mehr über die Forschungsmethodik zu erfahren, senden Sie eine Anfrage an unsere Branchenexperten.
Anpassung möglich
Data Bridge Market Research ist ein führendes Unternehmen in der fortgeschrittenen formativen Forschung. Wir sind stolz darauf, unseren bestehenden und neuen Kunden Daten und Analysen zu bieten, die zu ihren Zielen passen. Der Bericht kann angepasst werden, um Preistrendanalysen von Zielmarken, Marktverständnis für zusätzliche Länder (fordern Sie die Länderliste an), Daten zu klinischen Studienergebnissen, Literaturübersicht, Analysen des Marktes für aufgearbeitete Produkte und Produktbasis einzuschließen. Marktanalysen von Zielkonkurrenten können von technologiebasierten Analysen bis hin zu Marktportfoliostrategien analysiert werden. Wir können so viele Wettbewerber hinzufügen, wie Sie Daten in dem von Ihnen gewünschten Format und Datenstil benötigen. Unser Analystenteam kann Ihnen auch Daten in groben Excel-Rohdateien und Pivot-Tabellen (Fact Book) bereitstellen oder Sie bei der Erstellung von Präsentationen aus den im Bericht verfügbaren Datensätzen unterstützen.
